Symonds Steps Down As Novartis CFO, Replaced By Insider Kirsch
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis pharma division CFO Harry Kirsch is to replace Jon Symonds as group CFO. The company continues to benefit from the lack of a Diovan monotherapy generic in the U.S., reporting a 2% increase in sales and 7% increase in profits in the first quarter.